588 related articles for article (PubMed ID: 26423797)
1. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
[TBL] [Abstract][Full Text] [Related]
2. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
Bertucci F; Finetti P; Viens P; Birnbaum D
Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
[TBL] [Abstract][Full Text] [Related]
4. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
[TBL] [Abstract][Full Text] [Related]
5. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
6. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.
Khan SS; Karn T; Symmans WF; Rody A; Müller V; Holtrich U; Becker S; Pusztai L; Hatzis C
Breast Cancer Res Treat; 2015 Feb; 149(3):789-97. PubMed ID: 25651779
[TBL] [Abstract][Full Text] [Related]
7. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
9. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
11. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
13. A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.
Hamy AS; Bonsang-Kitzis H; Lae M; Moarii M; Sadacca B; Pinheiro A; Galliot M; Abecassis J; Laurent C; Reyal F
PLoS One; 2016; 11(12):e0167397. PubMed ID: 28005906
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients.
Naoi Y; Kishi K; Tsunashima R; Shimazu K; Shimomura A; Maruyama N; Shimoda M; Kagara N; Baba Y; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2013 Jul; 140(2):299-306. PubMed ID: 23884597
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
[TBL] [Abstract][Full Text] [Related]
17. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
18. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
Caparica R; Richard F; Brandão M; Awada A; Sotiriou C; de Azambuja E
Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175
[TBL] [Abstract][Full Text] [Related]
20. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
